Biogen Inc. (LON:0R1B)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 15.30B |
| Revenue (ttm) | 7.30B |
| Net Income (ttm) | 1.12B |
| Shares Out | n/a |
| EPS (ttm) | 7.63 |
| PE Ratio | 13.70 |
| Forward PE | 9.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 785 |
| Average Volume | 2,949 |
| Open | 139.83 |
| Previous Close | 141.88 |
| Day's Range | 137.51 - 142.98 |
| 52-Week Range | 110.20 - 204.00 |
| Beta | 0.11 |
| RSI | 61.51 |
| Earnings Date | Oct 31, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News
Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector
Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
Stocks making the biggest midday moves: Frontier Group, Kraft Heinz, Biogen and more
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest premarket moves: Kraft Heinz, PepsiCo, Biogen, Signet Jewelers and more
These are the stocks posting the largest moves in the premarket.
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More
Biogen wins approval of at-home version of Alzheimer's drug Leqembi
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option f...
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment
Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme...
FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi
The U.S. Food and Drug Administration said on Thursday it is recommending an additional, earlier magnetic resonance imaging monitoring prior to the third infusion for patients with Alzheimer's disease...
Biogen wins approval of postpartum depression drug Zurzuvae in UK
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard a...
Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news
Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biogen (BIIB) To Contact Him Directly To Discuss Their Options
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Biogen Inc. (NASDAQ: BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE: NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead ope...